Minimal Residual Disease–Guided Intermittent Dosing in Patients
With Cancer: Successful Treatment of Chemoresistant Anaplastic
Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

J 2022

Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

POKORNÁ, Petra, Giannoula KLEMENT, Alžběta VAŠÍKOVÁ, Veronika KANDEROVÁ, Marta JEŽOVÁ et. al.

Basic information

Original name

Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Authors

POKORNÁ, Petra (203 Czech Republic, belonging to the institution), Giannoula KLEMENT (300 Greece, belonging to the institution), Alžběta VAŠÍKOVÁ (203 Czech Republic, belonging to the institution), Veronika KANDEROVÁ (203 Czech Republic), Marta JEŽOVÁ (203 Czech Republic, belonging to the institution), Kristýna NOSKOVÁ (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Michal KÝR (203 Czech Republic, belonging to the institution), Tomáš MERTA (203 Czech Republic, belonging to the institution), Viera BAJČIOVÁ (703 Slovakia, belonging to the institution), Zdenka KŘENOVÁ (203 Czech Republic, belonging to the institution), Hana PÁLOVÁ (203 Czech Republic, belonging to the institution), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic, guarantor, belonging to the institution)

Edition

JCO PRECISION ONCOLOGY, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2022, 2473-4284

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.600

RIV identification code

RIV/00216224:14110/22:00126164

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1200/PO.21.00525

UT WoS

000814289300001

Keywords in English

intermitent dosing lorlatinib; chemoresistant lymphoma; minimal disseminated disease; pediatric oncology

Abstract

V originále

With the emergence of targeted therapies, the traditional maximum tolerated dosing where toxicities guide the treatment dose is no longer relevant. Especially in the case of tyrosine kinase inhibitors (TKIs), where higher doses lead to therapeutic resistance due to ligand or receptor upregulation and where off-target toxicities plague any increase of dose. In the case of TKIs, where the most effective dose is at the bottom of a U-shaped curve, therapy should be guided by biomarkers, or by minimal residual disease. We present a case of relapsed chemotherapy-refractory ALK-positive anaplastic large cell lymphoma treated with lorlatinib, where we used frequent minimal disseminated disease monitoring to guide the length of on/off therapy periods during intermitted dosing in order to prevent treatment resistance.

Links

MUNI/A/1427/2021, interní kód MU

Name: Personalizovaná léčba v dětské onkologii: na cestě k „liquid dynamic medicine“ a „N-of-1 clinical trials“

Investor: Masaryk University

NV19-03-00562, research and development project

Name: Využití globálních metylačních profilů a komplexní analýzy fúzních genů pro terapeutické plánování v dětské onkologii

Investor: Ministry of Health of the CR

90132, large research infrastructures

Name: NCMG II

Citovat

POKORNÁ, Petra, Giannoula KLEMENT, Alžběta VAŠÍKOVÁ, Veronika KANDEROVÁ, Marta JEŽOVÁ, Kristýna NOSKOVÁ, Peter MÚDRY, Michal KÝR, Tomáš MERTA, Viera BAJČIOVÁ, Zdenka KŘENOVÁ, Hana PÁLOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA. Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. JCO PRECISION ONCOLOGY. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2022, vol. 6, June 2022, p. 1-7. ISSN 2473-4284. Available from: https://dx.doi.org/10.1200/PO.21.00525.

@article{1863363,
   author = {Pokorná, Petra and Klement, Giannoula and Vašíková, Alžběta and Kanderová, Veronika and Ježová, Marta and Nosková, Kristýna and Múdry, Peter and Kýr, Michal and Merta, Tomáš and Bajčiová, Viera and Křenová, Zdenka and Pálová, Hana and Zdražilová Dubská, Lenka and Slabý, Ondřej and Valík, Dalibor and Štěrba, Jaroslav},
   article_location = {PHILADELPHIA},
   article_number = {June 2022},
   doi = {http://dx.doi.org/10.1200/PO.21.00525},
   keywords = {intermitent dosing lorlatinib; chemoresistant lymphoma; minimal disseminated disease; pediatric oncology},
   language = {eng},
   issn = {2473-4284},
   journal = {JCO PRECISION ONCOLOGY},
   title = {Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing},
   url = {https://ascopubs.org/doi/full/10.1200/PO.21.00525},
   volume = {6},
   year = {2022}
}

TY  - JOUR
ID  - 1863363
AU  - Pokorná, Petra - Klement, Giannoula - Vašíková, Alžběta - Kanderová, Veronika - Ježová, Marta - Nosková, Kristýna - Múdry, Peter - Kýr, Michal - Merta, Tomáš - Bajčiová, Viera - Křenová, Zdenka - Pálová, Hana - Zdražilová Dubská, Lenka - Slabý, Ondřej - Valík, Dalibor - Štěrba, Jaroslav
PY  - 2022
TI  - Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
JF  - JCO PRECISION ONCOLOGY
VL  - 6
IS  - June 2022
SP  - 1-7
EP  - 1-7
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 24734284
KW  - intermitent dosing lorlatinib
KW  - chemoresistant lymphoma
KW  - minimal disseminated disease
KW  - pediatric oncology
UR  - https://ascopubs.org/doi/full/10.1200/PO.21.00525
N2  - With the emergence of targeted therapies, the traditional maximum tolerated dosing where toxicities guide the treatment dose is no longer relevant. Especially in the case of tyrosine kinase inhibitors (TKIs), where higher doses lead to therapeutic resistance due to ligand or receptor upregulation and where off-target toxicities plague any increase of dose. In the case of TKIs, where the most effective dose is at the bottom of a U-shaped curve, therapy should be guided by biomarkers, or by minimal residual disease. We present a case of relapsed chemotherapy-refractory ALK-positive anaplastic large cell lymphoma treated with lorlatinib, where we used frequent minimal disseminated disease monitoring to guide the length of on/off therapy periods during intermitted dosing in order to prevent treatment resistance.
ER  -

POKORNÁ, Petra, Giannoula KLEMENT, Alžběta VAŠÍKOVÁ, Veronika KANDEROVÁ, Marta JEŽOVÁ, Kristýna NOSKOVÁ, Peter MÚDRY, Michal KÝR, Tomáš MERTA, Viera BAJČIOVÁ, Zdenka KŘENOVÁ, Hana PÁLOVÁ, Lenka ZDRAŽILOVÁ DUBSKÁ, Ondřej SLABÝ, Dalibor VALÍK and Jaroslav ŠTĚRBA. Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. \textit{JCO PRECISION ONCOLOGY}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2022, vol.~6, June 2022, p.~1-7. ISSN~2473-4284. Available from: https://dx.doi.org/10.1200/PO.21.00525.

Detailed Information on Publication Record